Print

Becton, Dickinson and Company (BDX) Announces Appointment of William A. Kozy as Chief Operating Officer  
11/6/2012 10:49:18 AM

FRANKLIN LAKES, N.J., Nov. 6, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William A. Kozy as Chief Operating Officer, effective today. Mr. Kozy adds this title to his current title of Executive Vice President. He will continue to report to Vincent A. Forlenza, Chairman, Chief Executive Officer and President.

"Bill's new title reflects his leadership role and the additional responsibilities that he has taken on over the last year, including oversight of BD's three business segments and working with me to drive BD's growth and innovation focus," said Mr. Forlenza.

Mr. Kozy, 60, joined BD in 1974 in a sales role in the BD Division selling laboratory products. This focus on blood collection eventually led to his first general management position as President of BD Vacutainer® Systems. His subsequent leadership positions include, among others, President, BD Worldwide Injection Systems; Senior VP, Company Operations; President, BD Diagnostics; and Executive Vice President.

Mr. Kozy has a B.A. cum laude in English from Kenyon College in Ohio.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contacts:
Colleen T. White, Corporate Communications 201-847-5369; colleen_white@bd.com
Monique N. Dolecki, Investor Relations 201-847-5378; monique_dolecki@bd.com

SOURCE BD (Becton, Dickinson and Company)


//-->